Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GLGC Gene Logic -- Ignore unavailable to you. Want to Upgrade?

To: Steve Lokness who wrote (302)	4/27/2007 3:50:45 PM
From: Mike McFarland	Respond to of 360

Sorta nice for me to see it fall back down to where I sold it: Had I held my shares none of the run-up would have done anything for me. I don't feel compelled to jump back in either-- another quarter of similar burn, pretty soon they're down to $35M, not much to work with. I'm a little more interested in buying back my INFI, if there is support somewhere around $10. However, looking a little closer at Nereus, I'd rather own that and don't really feel like I have to settle for infi. Some overlap which is interesting there, maybe that had something to do with Novartis. Of course infi already overlaps with kosn, hard to know if they really ought to have gone public. Maybe it is enough I got out of my dpii and that is the end of that. Looks like some citizen owners at infi are being paid quite well, I saw 200k share award for the ceo, not bad! But still no hedgehog? Quite a bonus... The last of my three pet biotechs that I watch is ANDS, which is off 5% today--I think it has simply drifted up with biotechs in general these past couple months. Again, just don't feel like I have to be in any of these since I am bearish on the market in general. So, let us say the market declines through the fall (when that decline starts...well, May is as good a guess as anything...) --biotech certainly wont do well in a bear market. Maybe something to be done with trading ASCO stocks, but I'll leave that for the experts. Cashboy was a good alias and I'm sticking to it.

To: Steve Lokness who wrote (302)	5/3/2007 11:43:00 AM
From: Mike McFarland	Read Replies (1) \| Respond to of 360

No doubt you have already seen this: Gene Logic has dismissed Mark Gessler washington.bizjournals.com From the latest annual report (which I have not read) Accumulated deficit (315,680) --That's $315M! They'll still have something on the order of $30 or $40M at the end of the year, but it is probably the bottom of the ninth inning, right? I've no position--I got half of a potentially great swing trade, so no complaints here. But you always wonder if they have a rabbit they can pull out of a hat. I do not think I will go back to the well however, I haven't been in this most of the past seven years and have been lucky. Gene Logic also paid Gessler's personal tax-preparation bills of $5,000 and annual country club dues of $6,440 last year. My taxes were filed for a little under $15 this year, nice!